Analytical Data
-
基因名
HLA-A*02:01&B2M&PRAME(SLLQHLIGL) Tetramer
- Application
-
别名
PRAME; OIP-4; OIP4; MAPE;
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A0A140T913 (G25-T305)&P61769
-
表达区间
A0A140T913 (G25-T305)&P61769 (I21-M119)&SLLQHLIGL
-
分子量
260-265 kDa under Non reducing (N)
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/PRAME (SLLQHLIGL) tetramer is a specialized recombinant protein complex that plays a crucial role in immunological research, particularly in the study of cancer immunotherapies. The HLA-A*02:01 molecule is one of the most commonly expressed major histocompatibility complex (MHC) class I molecules in humans, and it is pivotal for the presentation of antigenic peptides to CD8+ T cells. PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer/testis antigen that is overexpressed in various malignancies, making it a prime target for cancer immunotherapy. The specific peptide SLLQHLIGL, derived from PRAME, is recognized by T cells in the context of HLA-A*02:01, facilitating targeted immune responses against tumor cells. The development of tetramers that combine HLA-A*02:01, β2-microglobulin (B2M), and the PRAME-derived peptide allows for the precise identification and isolation of T cells that are reactive to PRAME, providing insights into immune responses in cancer patients. This tetrameric complex is a powerful tool for tracking T cell responses in both research and clinical settings, offering potential avenues for the design of peptide-based vaccines and adoptive T cell therapies aimed at enhancing anti-tumor immunity. Understanding the dynamics between the tetramer and T cell populations can pave the way for more effective cancer treatment strategies, highlighting the significance of this research in advancing precision medicine.
